Scinovex
article Open AccessTop 1% cited

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

European Journal of Cancer · 2019 · Vol. 109 · pp. 36–50
Sigbjørn SmelandStefan BielackJeremy WhelanMark L. BernsteinPancras C.W. HogendoornMark KrailoRichard GörlickKatherine A. JanewayFiona C. InglebyJakob AnningaImre AntalCarola ArndtKen BrownTrude Butterfaß‐BahloulGabriele CalaminusMichael CapraCatharina DhoogeMikael ErikssonAdrienne M. FlanaganGodehard FriedelMark C. GebhardtHans GelderblomRobert E. GoldsbyHolcombe E. GrierR. J. GrimerDouglas S. HawkinsStefanie Hecker‐NoltingKirsten Sundby HallMichael S. IsakoffGordana JovicThomas KühneLeo KagerThekla von KalleEdita KabíčkováSusanna LangChing C. LauPatrick J. LeaveyStephen L. LessnickLeo MascarenhasRegine Mayer‐SteinackerPaul A. MeyersRaj NagarajanR. Lor RandallPeter ReichardtMarleen RenardCatherine RechnitzerCindy L. SchwartzSandra J. StraussLisa A. TeotBeate TimmermannMatthew R. SydesNeyssa Marina

Abstract

In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.

Sarcoma Diagnosis and TreatmentCardiac tumors and thrombiVascular Tumors and AngiosarcomasOsteosarcomaMedicineCohortOverall survivalOncologyInternal medicinePathology

MeSH terms

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsChildCisplatinDoxorubicinFemaleFollow-Up StudiesHumansMaleMethotrexateNeoplasm MetastasisPrognosisOsteosarcoma

Funding

  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • Bayer
  • Novartis
  • Takeda Pharmaceuticals North America
  • European Science Foundation
  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung
  • Deutsche Krebshilfe
  • AstraZeneca Schweiz
  • Medical Research Council
Citations
709
FWCI
52.31
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.